OBIO CAAP Company: Winterlight Labs Enters New Collaboration with Johnson & Johnson Innovation

Johnson & Johnson Innovation facilitated an exclusive feasibility study between Janssen Research & Development, LLC and WinterLight Labs. The research will evaluate WinterLight’s proprietary technology for analyzing voice samples obtained from Janssen Research & Development’s ongoing clinical trials in Alzheimer’s and neurodegenerative diseases. The goal is to non-invasively predict dementia and neurodegenerative diseases long before clinical symptoms become apparent.

Read the press release

Previous
Previous

OBIO Pre-CAAP Company: Steadiwear Featured in Forbes Top Seven Startups For Souped-Up Senior Care

Next
Next

OBIO CAAP Companies Awarded Funding by Ontario Health Technologies Fund